 Robert Weinstein
Concepts (858)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cross Infection | 145 | 2021 | 293 | 16.390 |
Why?
| | Infection Control | 77 | 2021 | 171 | 8.720 |
Why?
| | Staphylococcal Infections | 44 | 2021 | 176 | 7.910 |
Why?
| | Anti-Bacterial Agents | 79 | 2021 | 412 | 7.850 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 31 | 2021 | 110 | 7.080 |
Why?
| | Intensive Care Units | 61 | 2021 | 316 | 4.910 |
Why?
| | Bacteremia | 35 | 2019 | 122 | 4.820 |
Why?
| | Drug Resistance, Bacterial | 18 | 2021 | 55 | 3.150 |
Why?
| | Humans | 312 | 2022 | 31481 | 3.020 |
Why?
| | Enterococcus | 26 | 2014 | 62 | 2.980 |
Why?
| | Drug Resistance, Microbial | 44 | 2015 | 96 | 2.890 |
Why?
| | Klebsiella pneumoniae | 19 | 2021 | 60 | 2.870 |
Why?
| | Community-Acquired Infections | 20 | 2021 | 77 | 2.730 |
Why?
| | Klebsiella Infections | 17 | 2020 | 55 | 2.610 |
Why?
| | Enterobacteriaceae Infections | 22 | 2021 | 48 | 2.540 |
Why?
| | Chlorhexidine | 19 | 2019 | 54 | 2.530 |
Why?
| | Gram-Positive Bacterial Infections | 22 | 2014 | 63 | 2.470 |
Why?
| | Disease Outbreaks | 29 | 2017 | 87 | 2.330 |
Why?
| | Catheterization, Central Venous | 17 | 2014 | 44 | 2.320 |
Why?
| | Chicago | 48 | 2021 | 955 | 2.180 |
Why?
| | Hospitals | 34 | 2020 | 142 | 2.120 |
Why?
| | Carrier State | 20 | 2019 | 52 | 2.090 |
Why?
| | Anti-Infective Agents | 13 | 2016 | 59 | 2.080 |
Why?
| | Surgical Wound Infection | 13 | 2019 | 106 | 2.050 |
Why?
| | beta-Lactamases | 18 | 2021 | 80 | 2.020 |
Why?
| | Bacterial Proteins | 17 | 2021 | 90 | 2.010 |
Why?
| | Carbapenems | 10 | 2019 | 32 | 2.000 |
Why?
| | Population Surveillance | 15 | 2018 | 127 | 1.980 |
Why?
| | AIDS-Related Opportunistic Infections | 19 | 2010 | 49 | 1.890 |
Why?
| | Anti-Infective Agents, Local | 15 | 2019 | 50 | 1.870 |
Why?
| | Drug Resistance, Multiple, Bacterial | 17 | 2020 | 49 | 1.780 |
Why?
| | Hand Disinfection | 14 | 2019 | 24 | 1.730 |
Why?
| | Enterobacteriaceae | 17 | 2020 | 39 | 1.720 |
Why?
| | Male | 127 | 2022 | 17583 | 1.680 |
Why?
| | Methicillin Resistance | 10 | 2012 | 33 | 1.670 |
Why?
| | Vancomycin | 15 | 2012 | 56 | 1.650 |
Why?
| | Baths | 10 | 2019 | 26 | 1.640 |
Why?
| | Vancomycin Resistance | 14 | 2014 | 31 | 1.640 |
Why?
| | Hospitalization | 20 | 2021 | 359 | 1.620 |
Why?
| | Staphylococcus aureus | 16 | 2021 | 87 | 1.610 |
Why?
| | Female | 124 | 2022 | 18253 | 1.590 |
Why?
| | Pneumonia, Pneumocystis | 19 | 2010 | 33 | 1.580 |
Why?
| | HIV Infections | 14 | 2013 | 951 | 1.570 |
Why?
| | Practice Guidelines as Topic | 13 | 2018 | 389 | 1.560 |
Why?
| | Bacterial Infections | 12 | 2021 | 71 | 1.550 |
Why?
| | Adult | 82 | 2022 | 9779 | 1.360 |
Why?
| | Middle Aged | 94 | 2022 | 11209 | 1.330 |
Why?
| | Probiotics | 2 | 2018 | 18 | 1.250 |
Why?
| | Equipment Contamination | 12 | 2019 | 27 | 1.240 |
Why?
| | Risk Factors | 39 | 2021 | 2664 | 1.240 |
Why?
| | Gloves, Protective | 7 | 2019 | 15 | 1.230 |
Why?
| | Medical Staff, Hospital | 3 | 2017 | 21 | 1.220 |
Why?
| | Internal Medicine | 3 | 2017 | 34 | 1.160 |
Why?
| | Skin | 12 | 2018 | 136 | 1.150 |
Why?
| | Communicable Diseases | 4 | 2016 | 18 | 1.150 |
Why?
| | Clostridium Infections | 4 | 2018 | 13 | 1.140 |
Why?
| | Prevalence | 19 | 2021 | 544 | 1.090 |
Why?
| | Gram-Negative Bacterial Infections | 9 | 2015 | 26 | 1.080 |
Why?
| | Guideline Adherence | 8 | 2014 | 77 | 1.060 |
Why?
| | Aged | 64 | 2022 | 10295 | 1.000 |
Why?
| | Illinois | 13 | 2021 | 266 | 1.000 |
Why?
| | Sepsis | 10 | 2014 | 157 | 0.970 |
Why?
| | Genomics | 6 | 2021 | 46 | 0.970 |
Why?
| | Microbial Sensitivity Tests | 28 | 2021 | 117 | 0.950 |
Why?
| | Antibiotic Prophylaxis | 5 | 2016 | 37 | 0.930 |
Why?
| | Drug Utilization | 8 | 2009 | 27 | 0.920 |
Why?
| | Drug Utilization Review | 3 | 2009 | 7 | 0.880 |
Why?
| | Catheters, Indwelling | 7 | 2006 | 30 | 0.880 |
Why?
| | Catheterization | 8 | 2007 | 62 | 0.860 |
Why?
| | Molecular Typing | 4 | 2021 | 9 | 0.860 |
Why?
| | United States | 39 | 2019 | 2539 | 0.850 |
Why?
| | Prisons | 3 | 2013 | 13 | 0.850 |
Why?
| | Mass Screening | 4 | 2015 | 199 | 0.840 |
Why?
| | Q Fever | 2 | 2016 | 5 | 0.830 |
Why?
| | Physicians | 6 | 2016 | 120 | 0.820 |
Why?
| | Hand | 6 | 2008 | 49 | 0.800 |
Why?
| | Personnel, Hospital | 7 | 2009 | 18 | 0.800 |
Why?
| | Tuberculosis, Pulmonary | 5 | 2009 | 8 | 0.790 |
Why?
| | Influenza, Human | 1 | 2021 | 52 | 0.790 |
Why?
| | Protective Clothing | 3 | 2019 | 10 | 0.780 |
Why?
| | Cost-Benefit Analysis | 4 | 2015 | 153 | 0.760 |
Why?
| | Long-Term Care | 11 | 2019 | 58 | 0.750 |
Why?
| | Health Care Costs | 3 | 2010 | 81 | 0.750 |
Why?
| | Catheter-Related Infections | 6 | 2014 | 26 | 0.750 |
Why?
| | Ventilation | 2 | 2017 | 4 | 0.750 |
Why?
| | DNA, Bacterial | 9 | 2019 | 54 | 0.750 |
Why?
| | Public Health | 3 | 2019 | 66 | 0.740 |
Why?
| | Evolution, Molecular | 2 | 2017 | 8 | 0.730 |
Why?
| | Models, Economic | 3 | 2010 | 10 | 0.730 |
Why?
| | Pseudomonas Infections | 14 | 2017 | 63 | 0.720 |
Why?
| | Patient Isolation | 8 | 2010 | 24 | 0.720 |
Why?
| | Quality of Health Care | 7 | 2005 | 141 | 0.720 |
Why?
| | Genotype | 4 | 2019 | 423 | 0.710 |
Why?
| | Smoke | 1 | 2018 | 4 | 0.710 |
Why?
| | Adolescent | 27 | 2022 | 2667 | 0.700 |
Why?
| | Hospitals, Teaching | 10 | 2018 | 37 | 0.700 |
Why?
| | Conflict of Interest | 1 | 2018 | 19 | 0.690 |
Why?
| | Retrospective Studies | 29 | 2021 | 3591 | 0.680 |
Why?
| | Case-Control Studies | 13 | 2022 | 687 | 0.670 |
Why?
| | Catheterization, Peripheral | 4 | 2002 | 18 | 0.670 |
Why?
| | Gram-Negative Bacteria | 12 | 2013 | 37 | 0.660 |
Why?
| | Infectious Disease Transmission, Professional-to-Patient | 3 | 2008 | 6 | 0.660 |
Why?
| | Primary Prevention | 1 | 2018 | 53 | 0.650 |
Why?
| | Genome, Bacterial | 5 | 2017 | 13 | 0.640 |
Why?
| | Medical Audit | 1 | 2017 | 8 | 0.640 |
Why?
| | Inappropriate Prescribing | 1 | 2017 | 5 | 0.640 |
Why?
| | Hospital Costs | 3 | 2014 | 73 | 0.630 |
Why?
| | Acquired Immunodeficiency Syndrome | 7 | 2006 | 100 | 0.630 |
Why?
| | Hospitals, Public | 11 | 2015 | 31 | 0.630 |
Why?
| | Nursing Homes | 7 | 2020 | 42 | 0.630 |
Why?
| | Bacterial Typing Techniques | 3 | 2016 | 12 | 0.630 |
Why?
| | Acinetobacter Infections | 3 | 2019 | 6 | 0.620 |
Why?
| | Patient Care | 3 | 2013 | 35 | 0.620 |
Why?
| | Nasal Cavity | 4 | 2014 | 36 | 0.610 |
Why?
| | Cesarean Section | 1 | 2016 | 33 | 0.600 |
Why?
| | Registries | 3 | 2022 | 214 | 0.600 |
Why?
| | Acinetobacter baumannii | 2 | 2019 | 5 | 0.590 |
Why?
| | Drug Resistance, Multiple | 6 | 2012 | 12 | 0.590 |
Why?
| | Lactobacillus | 1 | 2016 | 20 | 0.580 |
Why?
| | Critical Care | 8 | 2018 | 234 | 0.580 |
Why?
| | Doxycycline | 1 | 2016 | 23 | 0.580 |
Why?
| | State Medicine | 1 | 2015 | 3 | 0.580 |
Why?
| | Aerosols | 3 | 2013 | 23 | 0.570 |
Why?
| | Health Information Exchange | 1 | 2015 | 4 | 0.570 |
Why?
| | Length of Stay | 6 | 2014 | 377 | 0.570 |
Why?
| | Health Personnel | 4 | 2021 | 108 | 0.560 |
Why?
| | Health Resources | 2 | 2010 | 28 | 0.550 |
Why?
| | Anesthesia | 1 | 2015 | 29 | 0.540 |
Why?
| | Anesthesiology | 1 | 2015 | 28 | 0.530 |
Why?
| | Pharynx | 1 | 2014 | 14 | 0.520 |
Why?
| | Electrophoresis, Gel, Pulsed-Field | 12 | 2015 | 39 | 0.510 |
Why?
| | Medical Records Systems, Computerized | 3 | 2009 | 12 | 0.510 |
Why?
| | Urban Population | 3 | 2021 | 161 | 0.510 |
Why?
| | Platelet-Rich Plasma | 2 | 2016 | 67 | 0.510 |
Why?
| | Specimen Handling | 5 | 2017 | 50 | 0.510 |
Why?
| | Prospective Studies | 25 | 2019 | 1934 | 0.510 |
Why?
| | Sequence Analysis, DNA | 5 | 2017 | 81 | 0.500 |
Why?
| | Bacteria | 7 | 2017 | 74 | 0.500 |
Why?
| | Time Factors | 20 | 2022 | 1902 | 0.490 |
Why?
| | Pneumococcal Vaccines | 2 | 2004 | 5 | 0.490 |
Why?
| | Program Evaluation | 3 | 2009 | 153 | 0.480 |
Why?
| | Air Microbiology | 1 | 2013 | 3 | 0.470 |
Why?
| | Fungi | 1 | 2013 | 6 | 0.470 |
Why?
| | Child | 15 | 2021 | 1572 | 0.460 |
Why?
| | Disease Transmission, Infectious | 5 | 2019 | 22 | 0.460 |
Why?
| | Disease Notification | 2 | 2018 | 4 | 0.450 |
Why?
| | Students, Medical | 1 | 2012 | 46 | 0.450 |
Why?
| | Molecular Epidemiology | 9 | 2021 | 29 | 0.450 |
Why?
| | Alveolar Bone Loss | 2 | 2013 | 3 | 0.440 |
Why?
| | Mupirocin | 5 | 2019 | 15 | 0.440 |
Why?
| | Staphylococcal Skin Infections | 3 | 2011 | 14 | 0.440 |
Why?
| | Cephalosporins | 9 | 2019 | 18 | 0.440 |
Why?
| | Phenotype | 8 | 2021 | 379 | 0.440 |
Why?
| | Emergency Medical Services | 2 | 2014 | 40 | 0.430 |
Why?
| | Costs and Cost Analysis | 4 | 2010 | 39 | 0.430 |
Why?
| | Pharmacy Service, Hospital | 4 | 2006 | 10 | 0.430 |
Why?
| | Tertiary Care Centers | 4 | 2019 | 82 | 0.430 |
Why?
| | Multivariate Analysis | 12 | 2013 | 390 | 0.420 |
Why?
| | Streptococcal Infections | 2 | 2002 | 17 | 0.420 |
Why?
| | Communicable Disease Control | 5 | 2006 | 12 | 0.420 |
Why?
| | Water Microbiology | 3 | 2020 | 12 | 0.420 |
Why?
| | Gingival Recession | 1 | 2010 | 1 | 0.410 |
Why?
| | Furcation Defects | 1 | 2010 | 1 | 0.410 |
Why?
| | Evidence-Based Dentistry | 1 | 2010 | 1 | 0.410 |
Why?
| | Guidelines as Topic | 5 | 2009 | 79 | 0.410 |
Why?
| | Antiretroviral Therapy, Highly Active | 4 | 2010 | 151 | 0.410 |
Why?
| | Fluoroquinolones | 3 | 2019 | 25 | 0.400 |
Why?
| | Disinfectants | 3 | 2014 | 9 | 0.400 |
Why?
| | Hospital Mortality | 8 | 2010 | 192 | 0.400 |
Why?
| | HIV Seropositivity | 2 | 2004 | 98 | 0.390 |
Why?
| | Medical Records | 4 | 2005 | 40 | 0.390 |
Why?
| | Medicaid | 3 | 2006 | 43 | 0.390 |
Why?
| | Infant | 9 | 2021 | 642 | 0.390 |
Why?
| | Alcohols | 5 | 2007 | 7 | 0.390 |
Why?
| | Housekeeping, Hospital | 2 | 2008 | 5 | 0.390 |
Why?
| | Algorithms | 6 | 2014 | 412 | 0.380 |
Why?
| | Tuberculosis, Multidrug-Resistant | 2 | 2000 | 2 | 0.380 |
Why?
| | Hospital Information Systems | 2 | 2014 | 5 | 0.380 |
Why?
| | DNA Fingerprinting | 3 | 2016 | 6 | 0.370 |
Why?
| | Pseudomonas aeruginosa | 14 | 2017 | 85 | 0.370 |
Why?
| | Pharmacists | 2 | 2006 | 16 | 0.370 |
Why?
| | Respiration, Artificial | 7 | 2015 | 116 | 0.360 |
Why?
| | Hospitals, Urban | 8 | 2015 | 37 | 0.360 |
Why?
| | Infectious Disease Transmission, Patient-to-Professional | 1 | 2009 | 11 | 0.360 |
Why?
| | Soft Tissue Infections | 3 | 2011 | 25 | 0.360 |
Why?
| | Health Knowledge, Attitudes, Practice | 4 | 2008 | 230 | 0.360 |
Why?
| | Pandemics | 2 | 2021 | 203 | 0.360 |
Why?
| | Occupational Diseases | 1 | 2009 | 26 | 0.360 |
Why?
| | Child, Preschool | 8 | 2021 | 786 | 0.360 |
Why?
| | Escherichia coli | 7 | 2012 | 66 | 0.350 |
Why?
| | Rectum | 7 | 2017 | 72 | 0.350 |
Why?
| | Ceftazidime | 7 | 2001 | 13 | 0.350 |
Why?
| | Ambulatory Care | 2 | 2006 | 90 | 0.350 |
Why?
| | Feces | 4 | 2017 | 82 | 0.340 |
Why?
| | Pneumonia, Ventilator-Associated | 4 | 2015 | 18 | 0.340 |
Why?
| | Acinetobacter | 1 | 2008 | 2 | 0.340 |
Why?
| | Decontamination | 4 | 2008 | 10 | 0.340 |
Why?
| | Disinfection | 3 | 2019 | 13 | 0.340 |
Why?
| | Escherichia coli Infections | 6 | 2014 | 32 | 0.330 |
Why?
| | Delivery of Health Care | 2 | 2009 | 130 | 0.330 |
Why?
| | Drug Contamination | 3 | 2001 | 7 | 0.330 |
Why?
| | Skin Care | 4 | 2018 | 16 | 0.320 |
Why?
| | Public Housing | 1 | 2007 | 5 | 0.320 |
Why?
| | Developing Countries | 2 | 2005 | 22 | 0.320 |
Why?
| | Infant, Newborn | 9 | 2021 | 754 | 0.320 |
Why?
| | Penicillins | 3 | 2002 | 13 | 0.320 |
Why?
| | Incidence | 11 | 2013 | 829 | 0.310 |
Why?
| | Cohort Studies | 13 | 2022 | 2014 | 0.310 |
Why?
| | Amikacin | 4 | 1998 | 7 | 0.310 |
Why?
| | Pneumonia | 5 | 1998 | 74 | 0.310 |
Why?
| | Ciprofloxacin | 5 | 2003 | 28 | 0.310 |
Why?
| | Serratia Infections | 2 | 2010 | 10 | 0.310 |
Why?
| | Hospital Administration | 3 | 2021 | 25 | 0.310 |
Why?
| | Education, Medical | 1 | 2007 | 45 | 0.310 |
Why?
| | Dental Implantation, Endosseous | 2 | 2017 | 2 | 0.310 |
Why?
| | Young Adult | 8 | 2022 | 2277 | 0.310 |
Why?
| | Hospital Units | 2 | 2004 | 12 | 0.310 |
Why?
| | Enterobacter | 8 | 2001 | 8 | 0.300 |
Why?
| | Bacteriological Techniques | 6 | 2017 | 20 | 0.300 |
Why?
| | Cost of Illness | 1 | 2006 | 65 | 0.300 |
Why?
| | Rifampin | 1 | 2006 | 6 | 0.290 |
Why?
| | Referral and Consultation | 4 | 2007 | 99 | 0.290 |
Why?
| | Silver | 1 | 2006 | 4 | 0.290 |
Why?
| | Minocycline | 1 | 2006 | 8 | 0.290 |
Why?
| | Drug Therapy, Combination | 4 | 2011 | 265 | 0.290 |
Why?
| | Enterococcus faecium | 4 | 2001 | 16 | 0.290 |
Why?
| | Problem-Based Learning | 1 | 2006 | 11 | 0.290 |
Why?
| | Nose | 3 | 2013 | 35 | 0.290 |
Why?
| | Daptomycin | 1 | 2005 | 17 | 0.280 |
Why?
| | Information Services | 1 | 2005 | 4 | 0.280 |
Why?
| | Research | 1 | 2006 | 64 | 0.280 |
Why?
| | Dental Implants | 2 | 2017 | 8 | 0.280 |
Why?
| | Urinary Tract Infections | 5 | 2015 | 34 | 0.280 |
Why?
| | Education, Medical, Continuing | 1 | 2006 | 47 | 0.280 |
Why?
| | Pneumonia, Bacterial | 3 | 2017 | 15 | 0.280 |
Why?
| | Nursing Records | 1 | 2005 | 10 | 0.280 |
Why?
| | Aged, 80 and over | 18 | 2022 | 5234 | 0.280 |
Why?
| | Culture Media | 5 | 2017 | 44 | 0.280 |
Why?
| | Gram-Negative Aerobic Bacteria | 3 | 2005 | 4 | 0.270 |
Why?
| | Community Health Centers | 1 | 2005 | 14 | 0.270 |
Why?
| | Subacute Care | 2 | 2021 | 5 | 0.270 |
Why?
| | Streptococcus pneumoniae | 2 | 2002 | 7 | 0.270 |
Why?
| | Plasmids | 6 | 2019 | 52 | 0.270 |
Why?
| | Quality Indicators, Health Care | 1 | 2005 | 43 | 0.270 |
Why?
| | Dental Plaque | 1 | 2004 | 1 | 0.270 |
Why?
| | Mouthwashes | 1 | 2004 | 6 | 0.270 |
Why?
| | Communicable Diseases, Emerging | 1 | 2004 | 2 | 0.260 |
Why?
| | Bacterial Load | 3 | 2013 | 13 | 0.260 |
Why?
| | Point-of-Care Systems | 1 | 2004 | 29 | 0.260 |
Why?
| | Masks | 2 | 2021 | 4 | 0.260 |
Why?
| | Attitude of Health Personnel | 4 | 2014 | 181 | 0.260 |
Why?
| | Natural Language Processing | 1 | 2003 | 8 | 0.250 |
Why?
| | Diarrhea | 2 | 2008 | 50 | 0.250 |
Why?
| | Vaccination | 1 | 2004 | 43 | 0.250 |
Why?
| | Coxiella burnetii | 1 | 2003 | 4 | 0.250 |
Why?
| | Bioterrorism | 1 | 2003 | 6 | 0.250 |
Why?
| | Hospitals, University | 3 | 2015 | 46 | 0.250 |
Why?
| | Radiology | 1 | 2003 | 22 | 0.250 |
Why?
| | Colony Count, Microbial | 6 | 2015 | 24 | 0.250 |
Why?
| | Radiography, Thoracic | 1 | 2003 | 39 | 0.250 |
Why?
| | Health Behavior | 2 | 2021 | 177 | 0.250 |
Why?
| | Vancomycin-Resistant Enterococci | 2 | 2020 | 5 | 0.250 |
Why?
| | Unnecessary Procedures | 1 | 2004 | 30 | 0.250 |
Why?
| | Phylogeny | 3 | 2021 | 67 | 0.240 |
Why?
| | Ventilators, Mechanical | 2 | 2000 | 20 | 0.240 |
Why?
| | Databases as Topic | 1 | 2003 | 22 | 0.240 |
Why?
| | Digestive System Diseases | 1 | 2003 | 6 | 0.240 |
Why?
| | Computers | 1 | 2003 | 26 | 0.240 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 2003 | 84 | 0.240 |
Why?
| | RNA, Ribosomal, 16S | 3 | 2017 | 52 | 0.240 |
Why?
| | Treatment Outcome | 13 | 2018 | 3910 | 0.240 |
Why?
| | African Americans | 4 | 2021 | 818 | 0.240 |
Why?
| | Enterocolitis, Pseudomembranous | 2 | 2002 | 16 | 0.240 |
Why?
| | Critical Illness | 4 | 2018 | 125 | 0.240 |
Why?
| | Nursing Staff, Hospital | 1 | 2003 | 71 | 0.240 |
Why?
| | Patient Care Team | 3 | 2010 | 153 | 0.240 |
Why?
| | Gels | 1 | 2002 | 11 | 0.230 |
Why?
| | Infusions, Intravenous | 2 | 2005 | 89 | 0.230 |
Why?
| | Hospitals, Private | 1 | 2002 | 2 | 0.230 |
Why?
| | Hospitals, County | 1 | 2002 | 4 | 0.230 |
Why?
| | Water Supply | 1 | 2002 | 4 | 0.230 |
Why?
| | Renal Insufficiency | 1 | 2002 | 22 | 0.230 |
Why?
| | Gentamicins | 5 | 1995 | 15 | 0.230 |
Why?
| | Medication Systems | 1 | 2002 | 2 | 0.230 |
Why?
| | Cross-Over Studies | 3 | 2013 | 82 | 0.230 |
Why?
| | Penicillin Resistance | 1 | 2002 | 1 | 0.230 |
Why?
| | Quinine | 1 | 2002 | 1 | 0.230 |
Why?
| | Intestines | 3 | 2007 | 114 | 0.220 |
Why?
| | Patient Transfer | 2 | 2012 | 24 | 0.220 |
Why?
| | Legislation, Hospital | 1 | 2001 | 1 | 0.220 |
Why?
| | Cooperative Behavior | 2 | 2016 | 86 | 0.210 |
Why?
| | Sucralfate | 2 | 1991 | 3 | 0.210 |
Why?
| | Quality Improvement | 3 | 2018 | 173 | 0.210 |
Why?
| | Peer Review, Health Care | 1 | 2001 | 1 | 0.210 |
Why?
| | Selection Bias | 1 | 2001 | 9 | 0.210 |
Why?
| | Professional Staff Committees | 1 | 2001 | 9 | 0.210 |
Why?
| | APACHE | 3 | 2009 | 32 | 0.210 |
Why?
| | Spinal Puncture | 2 | 2000 | 23 | 0.210 |
Why?
| | Reproducibility of Results | 5 | 2014 | 886 | 0.210 |
Why?
| | Gammaproteobacteria | 1 | 2021 | 3 | 0.210 |
Why?
| | Emergency Service, Hospital | 3 | 2012 | 180 | 0.210 |
Why?
| | Homosexuality, Male | 2 | 2020 | 25 | 0.200 |
Why?
| | Environmental Microbiology | 2 | 2017 | 4 | 0.200 |
Why?
| | Skilled Nursing Facilities | 3 | 2015 | 19 | 0.200 |
Why?
| | Erythropoietin | 1 | 2001 | 50 | 0.200 |
Why?
| | Meningitis, Bacterial | 1 | 2000 | 9 | 0.200 |
Why?
| | Clinical Protocols | 1 | 2021 | 75 | 0.200 |
Why?
| | Iatrogenic Disease | 1 | 2000 | 26 | 0.200 |
Why?
| | Enterococcus faecalis | 2 | 1997 | 8 | 0.200 |
Why?
| | Neutropenia | 3 | 2008 | 26 | 0.200 |
Why?
| | Staphylococcus | 5 | 1993 | 11 | 0.200 |
Why?
| | Health Status Disparities | 1 | 2021 | 70 | 0.200 |
Why?
| | Fresh Water | 1 | 2020 | 5 | 0.190 |
Why?
| | Palliative Care | 1 | 2022 | 146 | 0.190 |
Why?
| | Klebsiella | 2 | 1999 | 2 | 0.190 |
Why?
| | Digestive System | 3 | 2000 | 19 | 0.190 |
Why?
| | Animals | 12 | 2017 | 5312 | 0.190 |
Why?
| | Epidemiology | 2 | 1998 | 5 | 0.190 |
Why?
| | Cross-Sectional Studies | 6 | 2021 | 986 | 0.190 |
Why?
| | Lung | 2 | 1998 | 171 | 0.190 |
Why?
| | Mycobacterium tuberculosis | 2 | 1998 | 17 | 0.190 |
Why?
| | Cardiac Surgical Procedures | 6 | 1988 | 98 | 0.180 |
Why?
| | Proportional Hazards Models | 4 | 2019 | 390 | 0.180 |
Why?
| | Risk Assessment | 4 | 2015 | 806 | 0.180 |
Why?
| | Tobramycin | 2 | 1998 | 11 | 0.180 |
Why?
| | Hospital Bed Capacity, 500 and over | 3 | 2012 | 9 | 0.180 |
Why?
| | Drug Costs | 2 | 2010 | 18 | 0.180 |
Why?
| | Medical Errors | 1 | 2019 | 31 | 0.180 |
Why?
| | Species Specificity | 2 | 2016 | 78 | 0.180 |
Why?
| | Hygiene | 4 | 2019 | 13 | 0.180 |
Why?
| | Workload | 2 | 2012 | 41 | 0.180 |
Why?
| | Risk | 7 | 2003 | 228 | 0.180 |
Why?
| | Genetic Variation | 3 | 2014 | 113 | 0.170 |
Why?
| | Consensus Development Conferences as Topic | 1 | 1998 | 6 | 0.170 |
Why?
| | Specialties, Nursing | 1 | 1998 | 11 | 0.170 |
Why?
| | Sensitivity and Specificity | 5 | 2018 | 580 | 0.170 |
Why?
| | Diagnostic Tests, Routine | 1 | 2018 | 16 | 0.170 |
Why?
| | Tuberculosis | 2 | 1997 | 24 | 0.160 |
Why?
| | HIV-1 | 4 | 1995 | 446 | 0.160 |
Why?
| | Logistic Models | 7 | 2019 | 479 | 0.160 |
Why?
| | American Hospital Association | 2 | 1994 | 2 | 0.160 |
Why?
| | Fomites | 2 | 2008 | 4 | 0.160 |
Why?
| | Decision Making, Computer-Assisted | 1 | 2017 | 6 | 0.160 |
Why?
| | Travel | 2 | 2014 | 15 | 0.160 |
Why?
| | Preservation, Biological | 1 | 1997 | 5 | 0.160 |
Why?
| | Feedback | 1 | 2017 | 26 | 0.160 |
Why?
| | Transfusion Reaction | 2 | 1995 | 9 | 0.160 |
Why?
| | Environment, Controlled | 1 | 2017 | 1 | 0.160 |
Why?
| | Greece | 1 | 2017 | 2 | 0.160 |
Why?
| | Latin America | 1 | 2017 | 7 | 0.160 |
Why?
| | Prognosis | 7 | 2022 | 1028 | 0.160 |
Why?
| | Israel | 1 | 2017 | 19 | 0.160 |
Why?
| | Regression Analysis | 6 | 2019 | 319 | 0.160 |
Why?
| | Microbiology | 1 | 2016 | 2 | 0.160 |
Why?
| | Bacterial Translocation | 4 | 2001 | 35 | 0.160 |
Why?
| | Endocarditis, Bacterial | 2 | 1996 | 17 | 0.150 |
Why?
| | Substance Abuse, Intravenous | 2 | 1996 | 12 | 0.150 |
Why?
| | Osseointegration | 1 | 2017 | 72 | 0.150 |
Why?
| | Respiratory Tract Infections | 3 | 1996 | 25 | 0.150 |
Why?
| | Jurisprudence | 1 | 1996 | 3 | 0.150 |
Why?
| | Gloves, Surgical | 1 | 1996 | 7 | 0.150 |
Why?
| | Health Care Surveys | 6 | 2014 | 77 | 0.150 |
Why?
| | Professional Role | 1 | 2016 | 26 | 0.150 |
Why?
| | Gram-Positive Bacteria | 3 | 2012 | 17 | 0.150 |
Why?
| | Sinus Floor Augmentation | 1 | 2016 | 1 | 0.150 |
Why?
| | Program Development | 1 | 2016 | 76 | 0.150 |
Why?
| | Maxilla | 1 | 2016 | 2 | 0.150 |
Why?
| | Quinolones | 1 | 1996 | 23 | 0.150 |
Why?
| | Pregnancy | 2 | 2016 | 457 | 0.150 |
Why?
| | beta-Lactam Resistance | 3 | 2017 | 16 | 0.150 |
Why?
| | Hydroxyapatites | 1 | 2016 | 9 | 0.150 |
Why?
| | RNA, Bacterial | 1 | 2016 | 3 | 0.150 |
Why?
| | Nontuberculous Mycobacteria | 2 | 2015 | 5 | 0.150 |
Why?
| | Pilot Projects | 4 | 2020 | 455 | 0.150 |
Why?
| | Mycobacterium Infections, Nontuberculous | 2 | 2015 | 8 | 0.150 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2016 | 47 | 0.150 |
Why?
| | Physician-Patient Relations | 1 | 1996 | 47 | 0.150 |
Why?
| | Equipment and Supplies | 2 | 2010 | 16 | 0.150 |
Why?
| | Titanium | 1 | 2017 | 204 | 0.150 |
Why?
| | Histiocytosis, Non-Langerhans-Cell | 1 | 1995 | 3 | 0.140 |
Why?
| | Bone Matrix | 1 | 2016 | 33 | 0.140 |
Why?
| | Histoplasmosis | 1 | 1995 | 9 | 0.140 |
Why?
| | Data Collection | 3 | 2006 | 120 | 0.140 |
Why?
| | Zidovudine | 2 | 1992 | 39 | 0.140 |
Why?
| | HIV Seronegativity | 1 | 1996 | 44 | 0.140 |
Why?
| | Candidiasis | 1 | 2015 | 23 | 0.140 |
Why?
| | Poisson Distribution | 3 | 2015 | 26 | 0.140 |
Why?
| | Thienamycins | 4 | 1998 | 7 | 0.140 |
Why?
| | Imipenem | 4 | 1998 | 7 | 0.140 |
Why?
| | Insurance, Health | 3 | 2003 | 27 | 0.140 |
Why?
| | Survival Analysis | 3 | 2008 | 379 | 0.140 |
Why?
| | Residence Characteristics | 2 | 2014 | 226 | 0.140 |
Why?
| | Nystatin | 1 | 1995 | 3 | 0.140 |
Why?
| | Colistin | 1 | 1995 | 5 | 0.140 |
Why?
| | Interferon-alpha | 2 | 1992 | 71 | 0.140 |
Why?
| | Cluster Analysis | 5 | 2015 | 55 | 0.140 |
Why?
| | Bacteriuria | 2 | 2015 | 6 | 0.140 |
Why?
| | Tuberculin Test | 2 | 2009 | 14 | 0.140 |
Why?
| | Communication | 1 | 1996 | 129 | 0.140 |
Why?
| | Diagnosis, Differential | 2 | 2016 | 467 | 0.140 |
Why?
| | Evidence-Based Medicine | 4 | 2008 | 239 | 0.140 |
Why?
| | Terminally Ill | 1 | 2014 | 5 | 0.130 |
Why?
| | Databases, Factual | 3 | 2019 | 391 | 0.130 |
Why?
| | Emigrants and Immigrants | 1 | 2014 | 25 | 0.130 |
Why?
| | Ventilator Weaning | 1 | 2015 | 33 | 0.130 |
Why?
| | Cost Savings | 1 | 2014 | 38 | 0.130 |
Why?
| | Severity of Illness Index | 8 | 2008 | 1240 | 0.130 |
Why?
| | Genetic Markers | 1 | 2014 | 51 | 0.130 |
Why?
| | Membrane Transport Proteins | 1 | 2014 | 51 | 0.130 |
Why?
| | Inpatients | 2 | 2009 | 154 | 0.120 |
Why?
| | Breast Diseases | 1 | 1993 | 6 | 0.120 |
Why?
| | Outpatient Clinics, Hospital | 2 | 2004 | 14 | 0.120 |
Why?
| | Surgical Procedures, Operative | 4 | 2013 | 40 | 0.120 |
Why?
| | Soaps | 4 | 2010 | 9 | 0.120 |
Why?
| | Blood | 2 | 2010 | 30 | 0.120 |
Why?
| | Drug Prescriptions | 3 | 2003 | 37 | 0.120 |
Why?
| | Abscess | 1 | 1993 | 23 | 0.120 |
Why?
| | Tooth Socket | 1 | 2013 | 1 | 0.120 |
Why?
| | Odds Ratio | 4 | 2021 | 327 | 0.120 |
Why?
| | Thailand | 1 | 2013 | 14 | 0.120 |
Why?
| | Models, Statistical | 4 | 2016 | 144 | 0.120 |
Why?
| | Drug Resistance | 2 | 2003 | 68 | 0.120 |
Why?
| | Hospital Departments | 2 | 2002 | 9 | 0.120 |
Why?
| | Longitudinal Studies | 5 | 2022 | 1452 | 0.120 |
Why?
| | Heart Failure | 1 | 2016 | 232 | 0.110 |
Why?
| | Multicenter Studies as Topic | 3 | 2001 | 73 | 0.110 |
Why?
| | Europe | 3 | 2014 | 88 | 0.110 |
Why?
| | Coronary Artery Bypass | 2 | 2011 | 75 | 0.110 |
Why?
| | Anti-HIV Agents | 2 | 2006 | 166 | 0.110 |
Why?
| | Burnout, Professional | 1 | 2012 | 41 | 0.110 |
Why?
| | Multilocus Sequence Typing | 3 | 2021 | 12 | 0.110 |
Why?
| | Epidemiologic Methods | 1 | 2012 | 22 | 0.110 |
Why?
| | Aspergillus niger | 1 | 1991 | 1 | 0.110 |
Why?
| | Charcoal | 1 | 1991 | 2 | 0.110 |
Why?
| | Paecilomyces | 1 | 1991 | 3 | 0.110 |
Why?
| | Penicillium | 1 | 1991 | 3 | 0.110 |
Why?
| | Pneumonia, Aspiration | 1 | 1991 | 9 | 0.110 |
Why?
| | Lung Diseases, Fungal | 1 | 1991 | 10 | 0.110 |
Why?
| | Emotions | 1 | 2012 | 98 | 0.110 |
Why?
| | Aspergillosis | 1 | 1991 | 14 | 0.110 |
Why?
| | Brucella | 1 | 2011 | 2 | 0.110 |
Why?
| | Brucellosis | 1 | 2011 | 3 | 0.110 |
Why?
| | Osteomyelitis | 2 | 2005 | 23 | 0.110 |
Why?
| | HIV | 1 | 2012 | 89 | 0.110 |
Why?
| | Quality Assurance, Health Care | 2 | 2010 | 54 | 0.110 |
Why?
| | Models, Biological | 1 | 2014 | 428 | 0.100 |
Why?
| | Patient Readmission | 1 | 2012 | 129 | 0.100 |
Why?
| | Serratia marcescens | 2 | 2010 | 11 | 0.100 |
Why?
| | Guided Tissue Regeneration, Periodontal | 1 | 2010 | 1 | 0.100 |
Why?
| | Peritoneal Diseases | 1 | 2010 | 4 | 0.100 |
Why?
| | Medical Office Buildings | 1 | 2010 | 1 | 0.100 |
Why?
| | Oropharynx | 1 | 1990 | 2 | 0.100 |
Why?
| | Gastrointestinal Diseases | 1 | 1991 | 42 | 0.100 |
Why?
| | Comorbidity | 3 | 2019 | 562 | 0.100 |
Why?
| | Efficiency | 1 | 2010 | 21 | 0.100 |
Why?
| | beta-Lactams | 3 | 2007 | 10 | 0.100 |
Why?
| | Blood Platelets | 1 | 2010 | 52 | 0.100 |
Why?
| | Cephalosporin Resistance | 2 | 2001 | 2 | 0.100 |
Why?
| | Medicare | 1 | 2011 | 113 | 0.100 |
Why?
| | Pancreatitis, Acute Necrotizing | 2 | 2001 | 4 | 0.100 |
Why?
| | Serratia | 3 | 2010 | 7 | 0.100 |
Why?
| | Kidney Diseases | 1 | 2012 | 146 | 0.100 |
Why?
| | Ecosystem | 2 | 2021 | 25 | 0.100 |
Why?
| | Knowledge Bases | 1 | 2010 | 3 | 0.100 |
Why?
| | Azlocillin | 1 | 1989 | 1 | 0.100 |
Why?
| | Hospitals, Special | 1 | 2009 | 6 | 0.100 |
Why?
| | Organizational Policy | 1 | 2009 | 16 | 0.090 |
Why?
| | Linear Models | 1 | 2010 | 276 | 0.090 |
Why?
| | Substance-Related Disorders | 4 | 2015 | 115 | 0.090 |
Why?
| | Patient Care Planning | 2 | 1995 | 58 | 0.090 |
Why?
| | Fever | 1 | 1989 | 38 | 0.090 |
Why?
| | Ventilators, Negative-Pressure | 1 | 2009 | 1 | 0.090 |
Why?
| | Urinary Catheterization | 2 | 2008 | 6 | 0.090 |
Why?
| | Patient Admission | 2 | 2002 | 34 | 0.090 |
Why?
| | Administration, Intranasal | 2 | 2019 | 25 | 0.090 |
Why?
| | Follow-Up Studies | 4 | 2019 | 2028 | 0.090 |
Why?
| | Drug Administration Schedule | 2 | 2008 | 257 | 0.090 |
Why?
| | Electronic Health Records | 1 | 2010 | 82 | 0.090 |
Why?
| | Predictive Value of Tests | 2 | 2010 | 637 | 0.090 |
Why?
| | Healthcare Disparities | 1 | 2010 | 82 | 0.090 |
Why?
| | Sputum | 3 | 2015 | 23 | 0.090 |
Why?
| | False Positive Reactions | 3 | 1998 | 40 | 0.090 |
Why?
| | Cefotaxime | 2 | 1986 | 5 | 0.090 |
Why?
| | Pancreatitis | 2 | 2000 | 29 | 0.090 |
Why?
| | Foodborne Diseases | 1 | 2008 | 3 | 0.090 |
Why?
| | Molecular Sequence Data | 2 | 2014 | 315 | 0.090 |
Why?
| | Lactams | 2 | 2005 | 6 | 0.080 |
Why?
| | Los Angeles | 5 | 2000 | 10 | 0.080 |
Why?
| | Antisepsis | 3 | 2003 | 3 | 0.080 |
Why?
| | Bedding and Linens | 1 | 2007 | 5 | 0.080 |
Why?
| | Folliculitis | 1 | 1987 | 1 | 0.080 |
Why?
| | Porifera | 1 | 1987 | 1 | 0.080 |
Why?
| | Health Facilities | 1 | 2007 | 11 | 0.080 |
Why?
| | Statistics, Nonparametric | 2 | 2004 | 156 | 0.080 |
Why?
| | Random Allocation | 4 | 2000 | 164 | 0.080 |
Why?
| | Renal Dialysis | 2 | 2015 | 117 | 0.080 |
Why?
| | Software | 2 | 2006 | 74 | 0.080 |
Why?
| | Cost Control | 1 | 2006 | 11 | 0.080 |
Why?
| | Inservice Training | 1 | 2006 | 30 | 0.080 |
Why?
| | Neoplasms | 1 | 1989 | 280 | 0.070 |
Why?
| | Aging | 1 | 1996 | 1614 | 0.070 |
Why?
| | Carbon | 1 | 2006 | 8 | 0.070 |
Why?
| | Platinum | 1 | 2006 | 6 | 0.070 |
Why?
| | Contact Tracing | 2 | 2011 | 6 | 0.070 |
Why?
| | Diagnostic Techniques and Procedures | 1 | 2005 | 5 | 0.070 |
Why?
| | Fellowships and Scholarships | 1 | 2006 | 38 | 0.070 |
Why?
| | Aminoglycosides | 6 | 1987 | 11 | 0.070 |
Why?
| | Bronchoscopy | 4 | 2003 | 38 | 0.070 |
Why?
| | Sex Factors | 3 | 2015 | 542 | 0.070 |
Why?
| | Quality of Life | 1 | 2010 | 663 | 0.070 |
Why?
| | Age Factors | 3 | 2004 | 943 | 0.070 |
Why?
| | AIDS Serodiagnosis | 1 | 2005 | 6 | 0.070 |
Why?
| | Survival Rate | 3 | 2003 | 465 | 0.070 |
Why?
| | Sexually Transmitted Diseases | 1 | 2005 | 16 | 0.070 |
Why?
| | Lumbosacral Region | 1 | 2005 | 71 | 0.070 |
Why?
| | Dental Plaque Index | 1 | 2004 | 1 | 0.070 |
Why?
| | Tooth Discoloration | 1 | 2004 | 1 | 0.070 |
Why?
| | Dental Implantation | 1 | 2004 | 2 | 0.070 |
Why?
| | Treatment Failure | 1 | 2005 | 187 | 0.070 |
Why?
| | Reagent Kits, Diagnostic | 1 | 2004 | 20 | 0.070 |
Why?
| | Societies, Medical | 1 | 2006 | 209 | 0.070 |
Why?
| | Zoonoses | 1 | 2004 | 9 | 0.070 |
Why?
| | Patient Participation | 1 | 2005 | 52 | 0.070 |
Why?
| | Health Planning | 1 | 2004 | 5 | 0.070 |
Why?
| | Severe Acute Respiratory Syndrome | 1 | 2004 | 3 | 0.070 |
Why?
| | Recombinant Proteins | 3 | 2001 | 295 | 0.070 |
Why?
| | Sanitary Engineering | 1 | 1984 | 1 | 0.060 |
Why?
| | Transducers | 3 | 1986 | 10 | 0.060 |
Why?
| | Analysis of Variance | 3 | 2017 | 364 | 0.060 |
Why?
| | Sentinel Surveillance | 1 | 2003 | 8 | 0.060 |
Why?
| | Radiology Information Systems | 1 | 2003 | 3 | 0.060 |
Why?
| | Pancreatic Diseases | 1 | 1983 | 4 | 0.060 |
Why?
| | Research Design | 1 | 2006 | 238 | 0.060 |
Why?
| | History, 20th Century | 2 | 2013 | 94 | 0.060 |
Why?
| | Monitoring, Physiologic | 3 | 1986 | 100 | 0.060 |
Why?
| | Sarcoidosis | 1 | 1983 | 15 | 0.060 |
Why?
| | Obstetrics and Gynecology Department, Hospital | 1 | 1983 | 4 | 0.060 |
Why?
| | Database Management Systems | 1 | 2003 | 1 | 0.060 |
Why?
| | Computer Systems | 1 | 2003 | 6 | 0.060 |
Why?
| | Blood-Borne Pathogens | 1 | 2003 | 5 | 0.060 |
Why?
| | Computer Communication Networks | 1 | 2003 | 5 | 0.060 |
Why?
| | Patient Acceptance of Health Care | 1 | 2004 | 85 | 0.060 |
Why?
| | Infant, Newborn, Diseases | 1 | 1983 | 18 | 0.060 |
Why?
| | Facility Design and Construction | 1 | 2003 | 2 | 0.060 |
Why?
| | Pregnancy Complications, Infectious | 1 | 1983 | 34 | 0.060 |
Why?
| | Models, Theoretical | 2 | 2021 | 112 | 0.060 |
Why?
| | Hospitals, Community | 1 | 2003 | 21 | 0.060 |
Why?
| | Kidney Function Tests | 1 | 2002 | 29 | 0.060 |
Why?
| | Hospitals, Municipal | 1 | 2002 | 1 | 0.060 |
Why?
| | Pneumococcal Infections | 1 | 2002 | 9 | 0.060 |
Why?
| | Home Care Services | 1 | 2002 | 27 | 0.060 |
Why?
| | New York City | 2 | 2000 | 23 | 0.060 |
Why?
| | Deoxycholic Acid | 1 | 2002 | 3 | 0.060 |
Why?
| | Patient Compliance | 1 | 2004 | 200 | 0.060 |
Why?
| | Blood Pressure Determination | 2 | 1986 | 22 | 0.060 |
Why?
| | Therapies, Investigational | 1 | 2022 | 6 | 0.060 |
Why?
| | Sequence Analysis, RNA | 1 | 2002 | 43 | 0.060 |
Why?
| | Medication Errors | 1 | 2002 | 20 | 0.060 |
Why?
| | Base Sequence | 1 | 2002 | 166 | 0.050 |
Why?
| | Animal Husbandry | 1 | 2001 | 6 | 0.050 |
Why?
| | North America | 1 | 2001 | 44 | 0.050 |
Why?
| | Gift Giving | 1 | 2021 | 1 | 0.050 |
Why?
| | Hand Sanitizers | 1 | 2021 | 1 | 0.050 |
Why?
| | Social Determinants of Health | 1 | 2022 | 22 | 0.050 |
Why?
| | Polymerase Chain Reaction | 3 | 2016 | 188 | 0.050 |
Why?
| | Methicillin | 1 | 2021 | 7 | 0.050 |
Why?
| | Intestinal Mucosa | 2 | 2001 | 235 | 0.050 |
Why?
| | Glucagon | 1 | 2001 | 6 | 0.050 |
Why?
| | Employment | 1 | 2021 | 39 | 0.050 |
Why?
| | Drug Therapy, Computer-Assisted | 1 | 2001 | 6 | 0.050 |
Why?
| | Confidentiality | 1 | 2001 | 12 | 0.050 |
Why?
| | Health Surveys | 1 | 2021 | 102 | 0.050 |
Why?
| | Meningitis | 2 | 1984 | 10 | 0.050 |
Why?
| | Lung Diseases | 2 | 1998 | 54 | 0.050 |
Why?
| | Health Education | 1 | 2001 | 50 | 0.050 |
Why?
| | Anticoagulants | 1 | 2002 | 151 | 0.050 |
Why?
| | Geography | 2 | 2011 | 22 | 0.050 |
Why?
| | Waste Disposal, Fluid | 1 | 2020 | 3 | 0.050 |
Why?
| | Peptides | 1 | 2001 | 116 | 0.050 |
Why?
| | Escherichia coli Proteins | 1 | 2020 | 14 | 0.050 |
Why?
| | Membrane Proteins | 1 | 2001 | 230 | 0.050 |
Why?
| | Lumbar Vertebrae | 1 | 2005 | 469 | 0.050 |
Why?
| | California | 1 | 2019 | 35 | 0.050 |
Why?
| | Respiratory Insufficiency | 1 | 2000 | 48 | 0.050 |
Why?
| | Platelet Activating Factor | 1 | 1999 | 8 | 0.050 |
Why?
| | Interleukin-6 | 1 | 2000 | 120 | 0.050 |
Why?
| | Leucine | 1 | 1999 | 18 | 0.050 |
Why?
| | Computer Simulation | 1 | 2021 | 249 | 0.050 |
Why?
| | Enteral Nutrition | 2 | 1998 | 64 | 0.050 |
Why?
| | Homes for the Aged | 1 | 1999 | 9 | 0.050 |
Why?
| | Haemophilus influenzae | 1 | 1999 | 1 | 0.050 |
Why?
| | Biopsy | 2 | 2017 | 283 | 0.040 |
Why?
| | Polymorphism, Restriction Fragment Length | 1 | 1998 | 7 | 0.040 |
Why?
| | Ear, Middle | 1 | 1999 | 7 | 0.040 |
Why?
| | Leukemia, Hairy Cell | 1 | 1978 | 2 | 0.040 |
Why?
| | Academic Medical Centers | 2 | 2010 | 158 | 0.040 |
Why?
| | ROC Curve | 1 | 2019 | 153 | 0.040 |
Why?
| | Imidazoles | 1 | 1999 | 74 | 0.040 |
Why?
| | Statistics as Topic | 1 | 1998 | 124 | 0.040 |
Why?
| | Homosexuality | 2 | 1995 | 9 | 0.040 |
Why?
| | Societies, Scientific | 1 | 1998 | 12 | 0.040 |
Why?
| | Patient Care Management | 1 | 1998 | 18 | 0.040 |
Why?
| | Gram-Positive Cocci | 2 | 2008 | 5 | 0.040 |
Why?
| | Hemodynamics | 1 | 1998 | 103 | 0.040 |
Why?
| | Nebulizers and Vaporizers | 1 | 1998 | 21 | 0.040 |
Why?
| | Hepatitis B | 2 | 1981 | 19 | 0.040 |
Why?
| | Dental Prosthesis Design | 1 | 2017 | 1 | 0.040 |
Why?
| | Acid Etching, Dental | 1 | 2017 | 2 | 0.040 |
Why?
| | Dental Alloys | 1 | 2017 | 4 | 0.040 |
Why?
| | Virus Diseases | 1 | 1997 | 15 | 0.040 |
Why?
| | Freezing | 1 | 1997 | 14 | 0.040 |
Why?
| | Microscopy, Electron, Scanning | 1 | 2017 | 81 | 0.040 |
Why?
| | Mycoses | 1 | 1997 | 23 | 0.040 |
Why?
| | Patient Education as Topic | 1 | 2019 | 192 | 0.040 |
Why?
| | Evidence-Based Practice | 1 | 2018 | 86 | 0.040 |
Why?
| | Agranulocytosis | 2 | 1989 | 7 | 0.040 |
Why?
| | Implants, Experimental | 1 | 2017 | 29 | 0.040 |
Why?
| | Temperature | 1 | 2017 | 85 | 0.040 |
Why?
| | Swine | 1 | 2017 | 117 | 0.040 |
Why?
| | Epidermal Growth Factor | 1 | 1997 | 33 | 0.040 |
Why?
| | Research Personnel | 1 | 2017 | 22 | 0.040 |
Why?
| | Surface Properties | 1 | 2017 | 139 | 0.040 |
Why?
| | Models, Animal | 1 | 2017 | 149 | 0.040 |
Why?
| | Hospital Bed Capacity | 1 | 1996 | 7 | 0.040 |
Why?
| | Confidence Intervals | 2 | 2012 | 102 | 0.040 |
Why?
| | Product Surveillance, Postmarketing | 1 | 1996 | 19 | 0.040 |
Why?
| | Selection, Genetic | 1 | 2016 | 6 | 0.040 |
Why?
| | Genes, Bacterial | 1 | 2016 | 8 | 0.040 |
Why?
| | Resuscitation Orders | 1 | 1996 | 5 | 0.040 |
Why?
| | Hospitals, Veterans | 1 | 1996 | 6 | 0.040 |
Why?
| | Teicoplanin | 1 | 1996 | 5 | 0.040 |
Why?
| | Ampicillin | 1 | 1996 | 8 | 0.040 |
Why?
| | Gastrointestinal Tract | 1 | 2017 | 52 | 0.040 |
Why?
| | Materials Testing | 1 | 2017 | 140 | 0.040 |
Why?
| | Sex Distribution | 1 | 1996 | 89 | 0.040 |
Why?
| | Sternum | 1 | 1976 | 5 | 0.040 |
Why?
| | Age Distribution | 1 | 1996 | 110 | 0.040 |
Why?
| | Mediastinitis | 1 | 1976 | 7 | 0.040 |
Why?
| | Ceramics | 1 | 2016 | 22 | 0.040 |
Why?
| | Bacterial Adhesion | 1 | 1996 | 6 | 0.040 |
Why?
| | Wounds and Injuries | 1 | 1996 | 58 | 0.040 |
Why?
| | Histoplasma | 1 | 1995 | 3 | 0.040 |
Why?
| | Bone Substitutes | 1 | 2016 | 34 | 0.040 |
Why?
| | Insurance, Hospitalization | 1 | 1995 | 2 | 0.040 |
Why?
| | Mucous Membrane | 1 | 1996 | 42 | 0.040 |
Why?
| | Candida | 1 | 2015 | 18 | 0.040 |
Why?
| | Guatemala | 1 | 1995 | 1 | 0.040 |
Why?
| | Cattle | 1 | 2016 | 260 | 0.040 |
Why?
| | Leadership | 1 | 2017 | 109 | 0.040 |
Why?
| | Diffusion | 2 | 2014 | 28 | 0.040 |
Why?
| | CD4 Lymphocyte Count | 1 | 1996 | 161 | 0.040 |
Why?
| | Cytokines | 1 | 1998 | 364 | 0.040 |
Why?
| | Staining and Labeling | 1 | 1975 | 27 | 0.040 |
Why?
| | Bisexuality | 1 | 1995 | 9 | 0.040 |
Why?
| | Osteogenesis | 1 | 2016 | 94 | 0.040 |
Why?
| | Urban Health Services | 1 | 2015 | 18 | 0.040 |
Why?
| | Markov Chains | 1 | 2015 | 32 | 0.040 |
Why?
| | Cerebrospinal Fluid | 1 | 1975 | 22 | 0.040 |
Why?
| | Florida | 4 | 1995 | 17 | 0.040 |
Why?
| | Intensive Care Units, Pediatric | 1 | 2015 | 14 | 0.040 |
Why?
| | Coagulase | 2 | 1993 | 2 | 0.030 |
Why?
| | Biocompatible Materials | 1 | 2016 | 112 | 0.030 |
Why?
| | Monte Carlo Method | 1 | 2015 | 56 | 0.030 |
Why?
| | Pulmonary Atelectasis | 1 | 2015 | 4 | 0.030 |
Why?
| | Gastric Juice | 1 | 2015 | 3 | 0.030 |
Why?
| | Drinking Water | 1 | 2015 | 4 | 0.030 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2015 | 19 | 0.030 |
Why?
| | Pentazocine | 2 | 1985 | 2 | 0.030 |
Why?
| | Tripelennamine | 2 | 1985 | 2 | 0.030 |
Why?
| | Pulmonary Edema | 1 | 2015 | 14 | 0.030 |
Why?
| | Syria | 1 | 2014 | 1 | 0.030 |
Why?
| | Management Audit | 1 | 2014 | 2 | 0.030 |
Why?
| | Epidemiological Monitoring | 1 | 2014 | 8 | 0.030 |
Why?
| | Virulence Factors | 1 | 2014 | 10 | 0.030 |
Why?
| | Tibia | 1 | 2017 | 266 | 0.030 |
Why?
| | Forecasting | 1 | 1995 | 134 | 0.030 |
Why?
| | Delirium | 1 | 2015 | 41 | 0.030 |
Why?
| | Minority Groups | 1 | 1995 | 79 | 0.030 |
Why?
| | Hand Hygiene | 1 | 2014 | 2 | 0.030 |
Why?
| | Thromboembolism | 1 | 2015 | 37 | 0.030 |
Why?
| | Health Services Accessibility | 1 | 1995 | 113 | 0.030 |
Why?
| | United States Occupational Safety and Health Administration | 1 | 1994 | 1 | 0.030 |
Why?
| | Organizational Culture | 1 | 2014 | 22 | 0.030 |
Why?
| | Planning Techniques | 1 | 1994 | 15 | 0.030 |
Why?
| | Campylobacter Infections | 1 | 2014 | 11 | 0.030 |
Why?
| | Acute Disease | 3 | 2000 | 254 | 0.030 |
Why?
| | Focus Groups | 1 | 2014 | 93 | 0.030 |
Why?
| | Nafcillin | 1 | 1993 | 1 | 0.030 |
Why?
| | Clindamycin | 1 | 1993 | 3 | 0.030 |
Why?
| | Longevity | 1 | 2014 | 35 | 0.030 |
Why?
| | History, 21st Century | 1 | 2013 | 39 | 0.030 |
Why?
| | Chickens | 1 | 2014 | 56 | 0.030 |
Why?
| | Rats, Sprague-Dawley | 3 | 2001 | 494 | 0.030 |
Why?
| | Drug Discovery | 1 | 2013 | 24 | 0.030 |
Why?
| | Publishing | 1 | 1994 | 37 | 0.030 |
Why?
| | Qualitative Research | 1 | 2014 | 127 | 0.030 |
Why?
| | Double-Blind Method | 1 | 1995 | 559 | 0.030 |
Why?
| | Comparative Effectiveness Research | 1 | 2013 | 9 | 0.030 |
Why?
| | Drainage | 1 | 1993 | 55 | 0.030 |
Why?
| | Alveolar Process | 1 | 2013 | 1 | 0.030 |
Why?
| | Alveolar Ridge Augmentation | 1 | 2013 | 1 | 0.030 |
Why?
| | Periodontium | 1 | 2013 | 1 | 0.030 |
Why?
| | Esthetics, Dental | 1 | 2013 | 2 | 0.030 |
Why?
| | Biopsy, Needle | 1 | 1993 | 117 | 0.030 |
Why?
| | Indiana | 2 | 2011 | 18 | 0.030 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2015 | 221 | 0.030 |
Why?
| | Surgical Flaps | 1 | 2013 | 54 | 0.030 |
Why?
| | Propensity Score | 1 | 2012 | 54 | 0.030 |
Why?
| | Rats | 3 | 2001 | 966 | 0.030 |
Why?
| | HIV Core Protein p24 | 1 | 1992 | 29 | 0.030 |
Why?
| | Leukocytes, Mononuclear | 1 | 1992 | 91 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2013 | 230 | 0.030 |
Why?
| | Lung Diseases, Obstructive | 1 | 1991 | 6 | 0.030 |
Why?
| | Splenomegaly | 1 | 2011 | 5 | 0.030 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2013 | 227 | 0.030 |
Why?
| | Virulence | 1 | 2011 | 13 | 0.030 |
Why?
| | Milk | 1 | 2011 | 10 | 0.030 |
Why?
| | Gastric Acidity Determination | 1 | 1991 | 2 | 0.030 |
Why?
| | Insurance Claim Reporting | 1 | 2011 | 1 | 0.030 |
Why?
| | Mexico | 1 | 2011 | 18 | 0.030 |
Why?
| | Hepatomegaly | 1 | 2011 | 6 | 0.030 |
Why?
| | Pneumonia, Staphylococcal | 1 | 2011 | 9 | 0.030 |
Why?
| | Administration, Topical | 1 | 1991 | 24 | 0.030 |
Why?
| | Immunocompromised Host | 1 | 1991 | 55 | 0.030 |
Why?
| | Prednisone | 1 | 1991 | 75 | 0.030 |
Why?
| | Comparative Genomic Hybridization | 1 | 2011 | 4 | 0.030 |
Why?
| | Clone Cells | 1 | 2011 | 21 | 0.030 |
Why?
| | Gene Frequency | 1 | 2011 | 80 | 0.030 |
Why?
| | Syringes | 1 | 2010 | 12 | 0.030 |
Why?
| | Pulmonary Embolism | 1 | 2011 | 57 | 0.030 |
Why?
| | Terminology as Topic | 1 | 2010 | 52 | 0.020 |
Why?
| | Bone Transplantation | 1 | 2013 | 231 | 0.020 |
Why?
| | Single-Blind Method | 1 | 2010 | 132 | 0.020 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 1993 | 224 | 0.020 |
Why?
| | Recurrence | 1 | 2011 | 389 | 0.020 |
Why?
| | Interviews as Topic | 1 | 2010 | 152 | 0.020 |
Why?
| | Automation | 1 | 2010 | 12 | 0.020 |
Why?
| | Decision Support Systems, Clinical | 1 | 2010 | 12 | 0.020 |
Why?
| | Adenocarcinoma | 1 | 1991 | 237 | 0.020 |
Why?
| | Ileum | 2 | 2001 | 31 | 0.020 |
Why?
| | Clinical Trials as Topic | 1 | 1991 | 378 | 0.020 |
Why?
| | Adrenal Cortex Hormones | 1 | 2010 | 100 | 0.020 |
Why?
| | Mutation | 3 | 1986 | 464 | 0.020 |
Why?
| | Escherichia coli O157 | 1 | 2008 | 2 | 0.020 |
Why?
| | Salmonella | 1 | 2008 | 5 | 0.020 |
Why?
| | Citrobacter | 1 | 1987 | 1 | 0.020 |
Why?
| | Oxacillin | 1 | 1987 | 3 | 0.020 |
Why?
| | Lymph Nodes | 2 | 1999 | 84 | 0.020 |
Why?
| | Drug Administration Routes | 1 | 2006 | 12 | 0.020 |
Why?
| | Allied Health Personnel | 1 | 2006 | 12 | 0.020 |
Why?
| | Decision Support Techniques | 1 | 2006 | 55 | 0.020 |
Why?
| | Transducers, Pressure | 1 | 1986 | 5 | 0.020 |
Why?
| | Environmental Monitoring | 1 | 2006 | 8 | 0.020 |
Why?
| | Diphtheria | 1 | 1985 | 1 | 0.020 |
Why?
| | Georgia | 2 | 1976 | 16 | 0.020 |
Why?
| | Nurses | 1 | 2006 | 51 | 0.020 |
Why?
| | Patients | 1 | 2006 | 26 | 0.020 |
Why?
| | Penicillanic Acid | 1 | 2005 | 3 | 0.020 |
Why?
| | Piperacillin | 1 | 2005 | 3 | 0.020 |
Why?
| | Metronidazole | 1 | 2005 | 9 | 0.020 |
Why?
| | Ceftriaxone | 1 | 2005 | 6 | 0.020 |
Why?
| | Deltaretrovirus | 1 | 1985 | 1 | 0.020 |
Why?
| | Blood Donors | 1 | 1985 | 7 | 0.020 |
Why?
| | Lung Neoplasms | 1 | 1991 | 756 | 0.020 |
Why?
| | Serotyping | 4 | 1987 | 12 | 0.020 |
Why?
| | Digestive System Surgical Procedures | 1 | 2005 | 27 | 0.020 |
Why?
| | Infant, Premature | 1 | 1986 | 226 | 0.020 |
Why?
| | Health Planning Guidelines | 1 | 2004 | 11 | 0.020 |
Why?
| | Ibuprofen | 1 | 1984 | 12 | 0.020 |
Why?
| | Moxalactam | 1 | 1983 | 1 | 0.020 |
Why?
| | Cefoxitin | 1 | 1983 | 2 | 0.020 |
Why?
| | Milk, Human | 1 | 1986 | 186 | 0.020 |
Why?
| | Nurseries, Hospital | 1 | 1983 | 5 | 0.020 |
Why?
| | Echinococcosis, Hepatic | 1 | 1983 | 1 | 0.020 |
Why?
| | Echinococcosis, Pulmonary | 1 | 1983 | 1 | 0.020 |
Why?
| | Mebendazole | 1 | 1983 | 1 | 0.020 |
Why?
| | Maternal-Fetal Exchange | 1 | 1983 | 11 | 0.020 |
Why?
| | Eosinophilia | 1 | 1984 | 49 | 0.020 |
Why?
| | Policy Making | 1 | 1983 | 16 | 0.020 |
Why?
| | Resource Allocation | 1 | 2003 | 5 | 0.010 |
Why?
| | Benzimidazoles | 1 | 1983 | 15 | 0.010 |
Why?
| | Blood Pressure Monitors | 1 | 2002 | 1 | 0.010 |
Why?
| | Umbilical Arteries | 1 | 2002 | 4 | 0.010 |
Why?
| | R Factors | 1 | 1982 | 2 | 0.010 |
Why?
| | Disease Reservoirs | 1 | 2002 | 10 | 0.010 |
Why?
| | Patient Selection | 1 | 2004 | 264 | 0.010 |
Why?
| | Plasmodium falciparum | 1 | 1981 | 4 | 0.010 |
Why?
| | Malaria | 1 | 1981 | 6 | 0.010 |
Why?
| | Glucagon-Like Peptides | 1 | 2001 | 2 | 0.010 |
Why?
| | Glucagon-Like Peptide 2 | 1 | 2001 | 2 | 0.010 |
Why?
| | Jejunum | 1 | 2001 | 14 | 0.010 |
Why?
| | Permeability | 1 | 2001 | 143 | 0.010 |
Why?
| | Conjugation, Genetic | 2 | 1996 | 5 | 0.010 |
Why?
| | Breast Feeding | 1 | 1983 | 177 | 0.010 |
Why?
| | Netilmicin | 1 | 1980 | 1 | 0.010 |
Why?
| | Pseudomonadaceae | 1 | 1980 | 1 | 0.010 |
Why?
| | Blood Cell Count | 1 | 2000 | 19 | 0.010 |
Why?
| | Weight Loss | 1 | 2001 | 114 | 0.010 |
Why?
| | Cecum | 1 | 2000 | 10 | 0.010 |
Why?
| | Urine | 1 | 1980 | 10 | 0.010 |
Why?
| | Pancreas | 1 | 2000 | 36 | 0.010 |
Why?
| | Dogs | 1 | 2000 | 283 | 0.010 |
Why?
| | Amylases | 1 | 1999 | 6 | 0.010 |
Why?
| | C-Reactive Protein | 1 | 2000 | 134 | 0.010 |
Why?
| | Rheumatic Fever | 1 | 1979 | 2 | 0.010 |
Why?
| | Gonorrhea | 1 | 1979 | 8 | 0.010 |
Why?
| | Carbon-Oxygen Ligases | 1 | 1999 | 2 | 0.010 |
Why?
| | Haemophilus Infections | 1 | 1999 | 2 | 0.010 |
Why?
| | Leukemia, Lymphoid | 1 | 1978 | 2 | 0.010 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 1999 | 230 | 0.010 |
Why?
| | Gastroenteritis | 1 | 1977 | 4 | 0.010 |
Why?
| | Cefazolin | 2 | 1988 | 6 | 0.010 |
Why?
| | Hepatitis | 1 | 1977 | 9 | 0.010 |
Why?
| | Skin Diseases, Infectious | 1 | 1977 | 9 | 0.010 |
Why?
| | Diagnostic Errors | 1 | 1977 | 48 | 0.010 |
Why?
| | Mesentery | 1 | 1997 | 6 | 0.010 |
Why?
| | Serum Albumin, Bovine | 1 | 1997 | 9 | 0.010 |
Why?
| | Postoperative Complications | 1 | 1985 | 1083 | 0.010 |
Why?
| | Laparotomy | 1 | 1997 | 25 | 0.010 |
Why?
| | Sterilization | 1 | 1976 | 10 | 0.010 |
Why?
| | Proteins | 1 | 1997 | 94 | 0.010 |
Why?
| | Pseudomonas | 1 | 1976 | 2 | 0.010 |
Why?
| | Sexual Behavior | 1 | 1996 | 71 | 0.010 |
Why?
| | Saphenous Vein | 1 | 1976 | 16 | 0.010 |
Why?
| | False Negative Reactions | 1 | 1975 | 16 | 0.010 |
Why?
| | North Carolina | 1 | 1995 | 12 | 0.010 |
Why?
| | Culture Techniques | 1 | 1975 | 38 | 0.010 |
Why?
| | Transplantation, Autologous | 1 | 1976 | 223 | 0.010 |
Why?
| | Laboratories | 1 | 1975 | 28 | 0.010 |
Why?
| | Leukocytes | 1 | 1975 | 50 | 0.010 |
Why?
| | Veterans | 1 | 1995 | 81 | 0.010 |
Why?
| | Isoelectric Focusing | 1 | 1993 | 7 | 0.010 |
Why?
| | Cloning, Molecular | 1 | 1993 | 47 | 0.010 |
Why?
| | Liver | 1 | 1975 | 214 | 0.010 |
Why?
| | Kinetics | 1 | 1993 | 278 | 0.010 |
Why?
| | AIDS-Related Complex | 1 | 1992 | 4 | 0.010 |
Why?
| | Injections, Subcutaneous | 1 | 1992 | 41 | 0.010 |
Why?
| | Leukocyte Count | 1 | 1992 | 96 | 0.010 |
Why?
| | Chemotherapy, Adjuvant | 1 | 1992 | 109 | 0.010 |
Why?
| | DNA, Viral | 1 | 1992 | 107 | 0.010 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 1992 | 225 | 0.010 |
Why?
| | Peritoneum | 1 | 1986 | 19 | 0.000 |
Why?
| | Disposable Equipment | 1 | 1986 | 2 | 0.000 |
Why?
| | Diphtheria Toxoid | 1 | 1985 | 1 | 0.000 |
Why?
| | Immunization, Secondary | 1 | 1985 | 6 | 0.000 |
Why?
| | Immunization | 1 | 1985 | 50 | 0.000 |
Why?
| | Seasons | 1 | 1985 | 36 | 0.000 |
Why?
| | Viremia | 1 | 1985 | 36 | 0.000 |
Why?
| | HIV Antibodies | 1 | 1985 | 39 | 0.000 |
Why?
| | Drug Interactions | 1 | 1985 | 70 | 0.000 |
Why?
| | Antibodies, Viral | 1 | 1985 | 79 | 0.000 |
Why?
| | Cardiac Catheterization | 1 | 1986 | 110 | 0.000 |
Why?
| | Injections, Intravenous | 1 | 1984 | 61 | 0.000 |
Why?
| | Cefamandole | 1 | 1983 | 1 | 0.000 |
Why?
| | Hydrolysis | 1 | 1983 | 16 | 0.000 |
Why?
| | Bone Marrow | 1 | 1983 | 68 | 0.000 |
Why?
| | Africa, Eastern | 1 | 1981 | 1 | 0.000 |
Why?
| | Proteus Infections | 1 | 1976 | 1 | 0.000 |
Why?
|
|
Weinstein's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|